Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide/rituximab (R(2)) vs rituximab/chemotherapy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Delfau-Larue, Marie-Helene, Boulland, Marie-Laure, Beldi-Ferchiou, Asma, Feugier, Pierre, Maisonneuve, Hervé, Casasnovas, Rene-Olivier, Lemonnier, François, Pica, Gian Matteo, Houot, Roch, Ysebaert, Loic, Tilly, Hervé, Eisenmann, Jean-Claude, Le Gouill, Steven, Ribrag, Vincent, Godmer, Pascal, Glaisner, Sylvie, Cartron, Guillaume, Xerri, Luc, Salles, Gilles André, Fest, Thierry, Morschhauser, Franck
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7391139/
https://ncbi.nlm.nih.gov/pubmed/32673385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001955
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares